Project Grant R03CA282712
Award Date
9/20/23
Completion Date
8/31/25
Dollars Obligated
$150K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This federal Project Grant award, valued at $465,020 and funded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research into the mechanisms by which chemotherapy can inadvertently promote metastasis in ovarian cancer. The research project, conducted by the University of Maryland, Baltimore, aims to determine how chemotherapy activates tumor-associated serine proteases (MASPs) that enable the spread and dissemination of ovarian cancer cells....
The National Cancer Institute (NCI) has awarded a $435,773 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Maryland, Baltimore (UMB) to develop an engineered prodrug capable of selectively delivering potent cytotoxins to malignant tumor cells. The goal is to leverage hyperactive membrane-anchored serine proteases (MASPs) on the surface of tumor cells to activate the prodrug and selectively kill cancer cells, particularly in ovarian, lung, and colon cancers. The...
This $936,746 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research (CFDA 93.396) program supports research at Rutgers, The State University of New Jersey to characterize the role of the BTLP3A gene in regulating mitochondrial stress responses and their impact on protective anti-tumor immunity in epithelial ovarian cancer. The research aims to leverage mouse models, reagents, and an extensive ovarian tumor bank to further understand how dysfunction in the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) in the amount of $612,288 provides funding to the University of Wisconsin-Madison to conduct research on the role of elevated collagen I and fibronectin in the ovarian cancer pre-metastatic niche for high-grade serous ovarian cancer (HGSOC). The 5-year project, beginning on December 11, 2024 and ending on November 30, 2029, aims to advance the fundamental understanding of the biological...
This federal Project Grant award of $552,763, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research to assess the therapeutic potential of newly developed KAT6 inhibitors (KAT6Is) as monotherapy and in combination with targeted therapies for high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC). The research, conducted by The Trustees of the University of Pennsylvania, aims to characterize the epigenetic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $800,888 to support research evaluating a combination therapy approach to overcome drug resistance in ovarian cancer patients. The key activities involve a Phase I clinical trial to assess the safety and tolerability of combining the CLK/DYRK inhibitor cirtuvivint with the PARP inhibitor olaparib in platinum-resistant ovarian cancer patients with BRCA/HRD...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $112,052 to The Trustees of the University of Pennsylvania to conduct research aimed at overcoming treatment resistance in gynecological cancers. The key products and services to be delivered include: Testing new therapies that exploit survival pathways critical for cancers with CCNE1 amplification, which are often platinum-resistant. This includes evaluating biomarkers beyond...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $2,186,372 to the University of California, Irvine to support a new program project on "Tipping Points in Cancer". The 5-year project, starting April 1, 2025, will investigate fundamental biological processes underlying cancer initiation and progression, using advanced mouse models of chronic myeloid leukemia, melanoma, and triple-negative breast cancer. The project will...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to support research on understanding the role of acetylcarnitine metabolism in ovarian cancer chemoresistance. The $1,373,308 award to the University of Pittsburgh will: Quantitatively and mechanistically map the acetylcarnitine-dependent histone acetylation axis and its contribution to homologous recombination-mediated DNA repair, which can promote chemoresistance in...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides funding of $1,104,864 to the University of California, Davis to conduct research on the molecular mechanisms of homologous recombination and chromosome maintenance. The research aims to understand how defects in the proteins involved in DNA pairing, including BRCA2 and the RAD51 paralogs, lead to chromosomal instability and cancer predisposition. The research will use biochemical...